17-35106385-C-T
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PVS1_ModeratePP5_Very_Strong
The NM_002878.4(RAD51D):c.576+1G>A variant causes a splice donor, intron change. The variant allele was found at a frequency of 0.00000372 in 1,612,668 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_002878.4 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD51D | ENST00000345365.11 | c.576+1G>A | splice_donor_variant, intron_variant | Intron 6 of 9 | 1 | NM_002878.4 | ENSP00000338790.6 | |||
ENSG00000267618 | ENST00000593039.5 | c.99+1G>A | splice_donor_variant, intron_variant | Intron 2 of 6 | 2 | ENSP00000466834.1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152212Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000402 AC: 1AN: 248838Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 134470
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1460456Hom.: 0 Cov.: 31 AF XY: 0.00000275 AC XY: 2AN XY: 726428
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152212Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74358
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 4 Pathogenic:4
This sequence change affects a donor splice site in intron 6 of the RAD51D gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in RAD51D are known to be pathogenic (PMID: 21822267). This variant is present in population databases (rs781161543, gnomAD 0.004%). Disruption of this splice site has been observed in individual(s) with endometrioid ovarian cancer (PMID: 22652533, 26261251). It is commonly reported in individuals of Finnish ancestry (PMID: 22652533, 26261251). In a small case-control study involving approximately 2000 cases and controls from Finland, this variant was shown to confer an increased risk for ovarian cancer in individuals with a personal or family history (OR 9.16, 95% CI 1.07 -78.56, p=0.024), with the highest risk in breast-ovarian cancer families (OR 37.82, 95% CI 3.90-366.91, p=0.0016) (PMID: 22652533). ClinVar contains an entry for this variant (Variation ID: 371839). Studies have shown that disruption of this splice site is associated with inconclusive levels of altered splicing (Invitae). For these reasons, this variant has been classified as Pathogenic. -
- -
This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. -
- -
not provided Pathogenic:3
- -
- -
The RAD51D c.576+1G>A variant disrupts a canonical splice-donor site and is predicted to result in the in-frame skipping of exon 6, which removes approximately 10% of the RAD51D protein and is expected to have an impact on protein function. In the published literature, this variant has been reported in multiple individuals with a personal or family history of breast/ovarian cancer (PMIDs: 32107557 (2020), 30927251 (2019), 29053726 (2017), 26261251 (2015)), and has been characterized as a founder mutation in the Finnish population (PMID: 22652533 (2012)). The frequency of this variant in the general population, 0.0000071 (2/280242 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is consistent with pathogenicity. Based on the available information, this variant is classified as likely pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.576+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 6 of the RAD51D gene. This variant has been reported in multiple individuals with personal history of breast and/or ovarian cancer, including male breast cancer (Pelttari LM et al. J. Med. Genet., 2012 Jul;49:429-32; Song H et al. J. Clin. Oncol., 2015 Sep;33:2901-7; Hallamies S et al. BMC Cancer, 2017 Sep;17:620; Nurmi A et al. Int. J. Cancer, 2019 Nov;145:2692-2700; Yang X et al. J Natl Cancer Inst, 2020 12;112:1242-1250). Haplotype analysis suggests this variant may be a Finnish founder mutation (Pelttari LM et al. J. Med. Genet., 2012 Jul;49:429-32). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and may result in the creation or strengthening of a novel splice donor site; however, direct evidence is insufficient at this time (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. -
Ovarian neoplasm Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at